Description

Adderall 30 mg (Mixed Amphetamine Salts) Tablets

Adderall 30 mg is a high-strength oral central nervous system ($\text{CNS}$) stimulant formulation composed of a specific 3:1 ratio of dextroamphetamine and levoamphetamine salts. It operates primarily by promoting the presynaptic release of dopamine and norepinephrine into the synaptic cleft while simultaneously blocking their reuptake via the dopamine transporter ($\text{DAT}$) and norepinephrine transporter ($\text{NET}$). This marked elevation in monoamine neurotransmission enhances executive function, impulse control, sustained attention, and wakefulness.

Product Overview

Primary Indications

Adderall 30 mg is indicated under licensed clinical supervision for:

• Attention-Deficit/Hyperactivity Disorder (ADHD): Integral component of a total treatment program for moderate-to-severe ADHD in patients requiring sustained executive function support and symptom control throughout the day.

• Narcolepsy: Treatment of excessive daytime sleepiness and cataplexy/sleep attack episodes associated with narcolepsy.

Key Information & Precautions

• Dosage & Titration (High Standard Strength): 30 mg represents the highest standard immediate-release single-tablet strength. In clinical practice, initial daily dosages for ADHD typically start at 5 mg to 10 mg once or twice daily; the 30 mg tablet is generally reserved for titrated maintenance dosing or divided doses using the score line.

• Boxed Warning — Abuse, Misuse, and Addiction: Amphetamines carry a high potential for abuse, non-medical diversion, and psychological/physiological dependence. Prolonged administration of high doses can lead to severe addiction, emotional instability, and stimulant-induced psychosis.

• Cardiovascular Risks: Amphetamines cause increases in blood pressure (averaging 2 to 4 mmHg) and heart rate (averaging 3 to 6 bpm). Use is contraindicated or requires extreme caution in individuals with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension, or structural cardiac abnormalities due to the risk of sudden cardiac death, myocardial infarction, and stroke.

• Psychiatric Complications: Stimulants may exacerbate pre-existing psychotic symptoms, precipitate manic episodes in patients with bipolar disorder, or provoke new-onset psychotic/manic symptoms (e.g., hallucinations, delusional thinking) at therapeutic dosages.

• Monoamine Oxidase Inhibitors (MAOIs): Concurrent administration with MAOIs—or within 14 days following discontinuation of an MAOI—is strictly contraindicated due to the risk of precipitating a fatal hypertensive crisis.

• Urinary pH Interactions: Agents that alter urinary pH markedly affect amphetamine excretion. Urinary alkalinizers (e.g., sodium bicarbonate, acetazolamide) decrease excretion and dramatically raise blood levels, whereas acidifying agents (e.g., ascorbic acid/vitamin C, ammonium chloride) accelerate clearance and lower efficacy.

• Discontinuation & Crash: Abrupt cessation following chronic high-dose therapy can induce extreme fatigue, severe depression, sleep pattern disruption, and psychomotor changes. Regimens should be discontinued under medical oversight.